| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/25/2000 | CA2350391A1 Method for inhibiting macrophage infiltration using monoclonal anti-alpha-d-antibodies |
| 05/25/2000 | CA2349869A1 Novel protein and utilization thereof |
| 05/25/2000 | CA2349488A1 Pentaaza-cyclopenta¬a|naphthalene derivatives as ligands for gabaa alpha5 receptors |
| 05/25/2000 | CA2348824A1 12 human secreted proteins |
| 05/25/2000 | CA2348676A1 Method for preparing (2s)-1-¬ (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulphonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl| pyrrolidine-2- carboxamide |
| 05/25/2000 | CA2348479A1 Novel members of the capsaicin/vanilloid receptor family of proteins and uses thereof |
| 05/25/2000 | CA2348459A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/24/2000 | EP1002862A1 Methods of diagnosing or treating neurological diseases |
| 05/24/2000 | EP1002796A2 Novel quinoxalindione derivatives, their production and use in medicaments |
| 05/24/2000 | EP1002794A1 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors |
| 05/24/2000 | EP1002534A1 Bis-Staurosporine and K-252a derivatives |
| 05/24/2000 | EP1002531A1 A water-miscible composition of non-steroidal antiinflammatory drugs |
| 05/24/2000 | EP1002099A1 Synaptojanin isoform |
| 05/24/2000 | EP1002074A1 Calcium-binding phosphoprotein |
| 05/24/2000 | EP1002071A1 Human glial cell line-derived neurotrophic factor promoters, vectors containing same, and methods of screening compounds therewith |
| 05/24/2000 | EP1001976A2 Peptides having potassium channel opener activity |
| 05/24/2000 | EP1001975A1 Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001974A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001973A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001972A1 Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001971A1 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001970A1 Dipeptide derivatives as growth hormone secretagogues |
| 05/24/2000 | EP1001956A1 New 2,3-benzodiazepine derivatives |
| 05/24/2000 | EP1001941A1 Fused heterocyclic compounds and their use as kynurenine-3-hydroxylase inhibitors |
| 05/24/2000 | EP1001940A1 Condensed pyrazole compounds |
| 05/24/2000 | EP1001933A1 Caspases and apoptosis |
| 05/24/2000 | EP1001814A1 Controlled release microencapsulated ngf formulation |
| 05/24/2000 | EP1001797A1 Soya extract, process for its preparation and pharmaceutical composition |
| 05/24/2000 | EP1001772A1 Improved delivery of multiple doses of medications |
| 05/24/2000 | EP1001764A1 Heterocyclic amide compounds as cell adhesion inhibitors |
| 05/24/2000 | EP1001762A1 Method of using neurotrophic carbamates and ureas |
| 05/24/2000 | EP1001761A1 Use of cholinesterase inhibitors for treating attention deficit disorders |
| 05/24/2000 | EP1001760A1 Composition for controlling mood disorders in healthy individuals |
| 05/24/2000 | EP1001755A2 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| 05/24/2000 | EP1001753A1 Low dosed 15-desoxyspergualine preparations |
| 05/24/2000 | EP1001752A1 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
| 05/24/2000 | EP0817767B1 Bicyclic amine derivatives and their use as anti-psychotic agents |
| 05/24/2000 | EP0671879B1 Prevention of injury and degeneration of photoreceptors by neurotrophic factors |
| 05/24/2000 | EP0637315B1 Adenosine derivatives having a2 agonist activity |
| 05/24/2000 | CN1254345A Serine protease inhibitors |
| 05/24/2000 | CN1254344A Estrogenic 10-Noradnrost-17-one derivatives with aromatic B-ring |
| 05/24/2000 | CN1254343A Pregnane 3,20 diol mono- and di-sulphates |
| 05/24/2000 | CN1254342A Pharmaceutically acceptable salts of 5 alpha-pregnan-3-beta, 16 alpha-diol-20-one 3-sulfate useful as progestins and CNS disorders |
| 05/24/2000 | CN1254341A Pharmaceutically accpetable salts of 3-hydroxy-estr-5-(10)-en-17-one 3-sulphate active as estrogens |
| 05/24/2000 | CN1254337A N-hydroxy 4-sulfonyl butyramide compounds |
| 05/24/2000 | CN1254335A Nicotinamide derivatives |
| 05/24/2000 | CN1254294A Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
| 05/24/2000 | CN1254283A Pregnan-3-ol-20-ones |
| 05/24/2000 | CN1253807A Tea with functions of dispelling effect of alcohol, nourishing stomach and protecting liver |
| 05/24/2000 | CN1253775A Refractory vasculitis therapeutic preparation |
| 05/24/2000 | CN1052731C Compounds with growth hormone releasing properties |
| 05/24/2000 | CN1052730C Compounds with growth hormone releasing properties |
| 05/24/2000 | CN1052726C 7-azabicyclo-[2,2,1]-heptane and-heptene derivatives as analgesics and anti-inflammatory agents |
| 05/24/2000 | CN1052723C Bicyclic aromatic compounds as therapeutic agents, its preparing method and drug composition containing said compound |
| 05/24/2000 | CN1052722C Dibenzooxapine or thiapine derivative, its preparing method and drug composition |
| 05/24/2000 | CN1052636C Application of shiny-leaved yellowhorn alcohol extract in preparing drug for curing hypophrenia |
| 05/23/2000 | US6066737 Process for the preparation of optically enriched 4-aryl-3-hydromethyl substituted piperidines to be used as intermediates in the synthesis of paroxetine |
| 05/23/2000 | US6066717 RsbW-1 protein |
| 05/23/2000 | US6066663 Oxidation derivatives of indolylalkylamines and their use as drugs |
| 05/23/2000 | US6066657 For the treatment of disease states associated with proteins which mediate cellular activity, for example by inhibiting tumor necrosis factor or phosphodiesterase iv |
| 05/23/2000 | US6066655 For the treatment of central nervous system disorders, in particular as cerebral therapeutics |
| 05/23/2000 | US6066644 Treatment of various cns disorders |
| 05/23/2000 | US6066643 Administering to said mammal an effective amount of moxonidine, or a pharmaceutically acceptable salt thereof |
| 05/23/2000 | US6066642 For selectively blocking the a3 adenosine receptor of a mammal |
| 05/23/2000 | US6066641 Phosphodiesterases as molecular targets for anti-asthmatic agents |
| 05/23/2000 | US6066627 Steroids as neurochemical initiators of change in human blood levels of LH |
| 05/23/2000 | US6066502 Endothelin converting enzyme (ECE) |
| 05/23/2000 | US6066339 Controlled release coating of ammonia methacrylate copolymer |
| 05/23/2000 | US6066320 Isolating antiserum with nerve cells presenting anti-prion protein |
| 05/23/2000 | US6066092 Preemptive prophylaxis of migraine device and method |
| 05/23/2000 | CA2200959C 2,7-substituted octahydro-1h-pyrido[1,2-a]pyrazine derivatives |
| 05/23/2000 | CA2171637C Substituted azaheterocyclecarboxylic acids |
| 05/23/2000 | CA2104873C Compositions and methods of treatment of sympathetically maintained pain |
| 05/23/2000 | CA2010578C Piperidine compounds and their preparation and use |
| 05/18/2000 | WO2000028062A1 Novel system for regulating transgene expression |
| 05/18/2000 | WO2000028059A1 Adenovirus-mediated gene therapy |
| 05/18/2000 | WO2000028045A2 Human hydrolase proteins |
| 05/18/2000 | WO2000028041A1 Delivery of superoxide dismutase to neuronal cells |
| 05/18/2000 | WO2000028029A2 Cell surface glycoproteins |
| 05/18/2000 | WO2000028022A1 Pge synthase and methods and means for modulating its activity |
| 05/18/2000 | WO2000028010A2 The genetic determination of genes and its use for the prophylaxis and therapy of diseases |
| 05/18/2000 | WO2000028004A1 Virus vectors and methods of making and administering the same |
| 05/18/2000 | WO2000027874A2 Nucleic acids encoding transferrin receptor-like proteins and products related thereto |
| 05/18/2000 | WO2000027851A1 Novel type condensed pyridazinone compounds |
| 05/18/2000 | WO2000027850A2 Crf receptor antagonists and methods relating thereto |
| 05/18/2000 | WO2000027849A2 Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
| 05/18/2000 | WO2000027846A2 Crf receptor antagonists and methods relating thereto |
| 05/18/2000 | WO2000027845A1 Spiro-indolines as y5 receptor antagonists |
| 05/18/2000 | WO2000027823A1 Gastrin and cholecystokinin receptor ligands |
| 05/18/2000 | WO2000027815A2 N-substituted azacycles, their preparation and their use as orl-1 receptor ligands |
| 05/18/2000 | WO2000027811A1 Neurotrophic diamide and carbamate agents |
| 05/18/2000 | WO2000027805A1 Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
| 05/18/2000 | WO2000027799A1 New esters derived from substituted phenyl-cyclohexyl compounds |
| 05/18/2000 | WO2000027432A1 USE OF AN ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS |
| 05/18/2000 | WO2000027422A2 Methods and compositions for treating or preventing peripheral neuropathies |
| 05/18/2000 | WO2000027418A2 A method for treating tissue damaged from ischemia |
| 05/18/2000 | WO2000027412A1 Use of extracts of eschscholzia californica for producing medicaments for treating depression |
| 05/18/2000 | WO2000027400A1 Use of agonists of glucocorticosteroid receptors and/or mineral corticosteroid receptors, especially corticosteroids to treat addictions |
| 05/18/2000 | WO2000027392A1 Chromone enteric release formulation |
| 05/18/2000 | WO2000027385A1 Dispersible compositions containing l-dopa ethyl ester |